Metsera to Showcase Next-Generation Obesity Therapies at ADA 2025 with Clinical Data from Ultra-Long Acting GLP-1 Agonist
核心洞察
Metsera will present clinical data from its completed Phase 1/2 trial of MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, at the 85th Scientific Sessions of the American Diabetes Association.
The company will showcase seven presentations highlighting its portfolio of ultra-long acting therapies, including preclinical data on MET-233i, a monthly amylin analog for obesity treatment.
Clinical presentations will include body weight changes and tolerability data after twelve weekly doses and a single candidate monthly dose of MET-097i.
Metsera, Inc. (Nasdaq: MTSR) will present comprehensive clinical and preclinical data from its next-generation obesity therapy portfolio at the 85th Scientific Sessions of the American Diabetes Association (ADA) on June 22, 2025. The clinical-stage biopharmaceutical company will showcase seven presentations highlighting its ultra-long acting, scalable, and combinable therapeutic approaches for obesity and metabolic diseases.
Clinical Data from Lead Program MET-097i
The centerpiece of Metsera's ADA presentations will be clinical data from MET-097i, the company's fully biased, monthly, ultra-long acting GLP-1 receptor agonist. Two clinical presentations will detail findings from the completed Phase 1/2 trial, including body weight changes and tolerability data following twelve weekly doses and after a single candidate monthly dose.
"Our presentations, including clinical data from the completed Phase 1/2 trial of MET-097i and preclinical findings for our other programs, showcase the breadth of our next-generation approaches to address the need for scalable and differentiated treatments for overweight and obesity," said Whit Bernard, Chief Executive Officer of Metsera.
Dr. Robert Stoekenbroek, Head of Portfolio Strategy at Metsera, will present "A Twelve-Week Trial of MET-097—A Potent and Ultra-Long-Acting GLP-1 Receptor Agonist," while Dr. Steve Marso, Chief Medical Officer, will discuss "Safety, Tolerability, PK, and Efficacy of MET-097—A Next-Generation Nutrient-Stimulated Hormone Peptide Analog for Chronic Weight Management."
Preclinical Portfolio Advances
Beyond MET-097i, Metsera will present preclinical data on MET-233i, its monthly, ultra-long acting amylin analog. The presentation will include detailed pharmacokinetic and body weight change data, demonstrating the company's expansion beyond GLP-1 receptor targeting.
Dr. James S. Minnion, Vice President of Research & Development at Metsera, will present findings titled "MET-233 Is an Ultra-Long-Acting Amylin Receptor Agonist," highlighting the therapeutic potential of this novel approach to obesity treatment.
Combination Therapy Research
A particularly notable presentation will focus on "Therapeutic NuSH Cocktails," examining the coadministration of ultra-long acting GLP-1, GIP (搜索), glucagon, and amylin peptide analogs. According to the research to be presented by Dr. Robert Hansford, Preclinical Research Scientist at Metsera, these combination approaches induced profound weight loss in diet-induced obesity (DIO) mice models.
Real-World Evidence and Market Access
Metsera will also present health economics and outcomes research addressing current treatment challenges. Shannon Armstrong, Vice President of Global Value and Access, will present findings on "Titration to Maintenance Doses of GLP-1R Agonists for Overweight and Obesity Is Suboptimal for Majority of Patients—Evidence from a Real-World Claims Dataset."
Company Portfolio Strategy
Founded in 2022 and based in New York City, Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies. The company's approach focuses on developing treatments with potential best-in-class profiles to address multiple therapeutic targets in the rapidly evolving weight loss treatment landscape.
The comprehensive presentation schedule demonstrates Metsera's commitment to advancing multiple therapeutic modalities simultaneously, from its lead clinical program to early-stage combination approaches that could potentially address the complex pathophysiology of obesity through multiple mechanisms of action.